Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

PHASE3RecruitingINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

February 27, 2022

Primary Completion Date

February 1, 2026

Study Completion Date

July 31, 2026

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

AZM Group

AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.

OTHER

Control Group

Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.

Trial Locations (10)

20010

RECRUITING

Children's National Hospital, Washington D.C.

35233

RECRUITING

The University of Alabama at Birmingham, Birmingham

43205

RECRUITING

Nationwide Children's Hospital, Columbus

44106

RECRUITING

Rainbow Babies and Children's Hospital, Cleveland

46202

RECRUITING

Riley Children's Health, Indianapolis

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

68198

RECRUITING

University of Nebraska Medical Center, Omaha

73104

RECRUITING

Oklahoma Health Sciences, Oklahoma City

94143

RECRUITING

University of California San Francisco, San Francisco

06520-8064

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER